Cellectis to Host Webinar on Clinical Progress
Cellectis announces a webinar on December 4, 2025, to showcase its clinical and strategic advancements.
Presentation of Key Clinical Data
According to the press release, Cellectis, a biotechnology company listed on Euronext Growth and Nasdaq, will present significant clinical data for its product lasmé-cel during the webinar. Designed for patients with relapsed or refractory B-cell acute lymphoblastic leukemia, this product was discussed during the R&D Day on October 16, 2025. The company also plans to discuss the design of the pivotal Phase 2 clinical trial, the registration pathway, and the commercial potential of lasmé-cel, estimated to reach up to about $700 million in annual sales at peak.
Future Directions for éti-cel Program
Cellectis will also discuss the next steps for the éti-cel program, targeting patients with relapsed or refractory non-Hodgkin lymphoma. The webinar will include a review of the company's strategic collaborations and recent advancements in genome editing. Cellectis' executives will answer questions from the audience, which were previously submitted via email.
Webinar Details
The webinar is scheduled for December 4, 2025, at 2:00 PM Paris time, and will be hosted by Dr. André Choulika, Dr. Laurent Poirot, and Arthur Stril. Participants can register via a link provided in the press release, and a recording of the event will be available later on Cellectis' website.
